The Leading Edge of Precision Oncology

Precision Medicine is Driving a New Era in Oncology Drug Development

Biopharma companies are at the forefront of introducing novel targeted therapies, redefining the therapeutic management of cancer. These treatments target the specific alterations or biomarkers of a patient's cancer, which can significantly extend progression-free survival compared to traditional chemotherapy or immunotherapy.1-7

Helping Pharmaceutical Companies Accelerate Precision Oncology Drug Development

From translational research to clinical development to commercialization, our portfolio is designed to seamlessly meet your needs at each stage of research and development—all while refining focus and accelerating your outcomes.

Precision oncology is an essential part of the future of cancer care, which may one day even include targeted interventional therapies to help prevent disease progression at earlier stages.

Pioneering Multiomic Approaches to Power Precision Oncology with Deeper Insights

Our portfolio of innovative solutions and best-in-class service spans:

Ensure your drug development programs stay ahead of the curve with Guardant Infinity™. A single assay tailored to fit your needs providing comprehensive genomic and epigenomic profiling insights for biomarker discovery and development of cancer therapies today and beyond.

Guardant360® CDx is a comprehensive liquid biopsy for all advanced solid tumors that is approved as a companion diagnostic for multiple targeted therapies.8 With a growing pipeline of diagnostic claims and an expanding global network, Guardant Health can help accelerate clinical development and commercial success.

Let’s Get Started

Contact our Biopharma team to see how we can help you accelerate precision oncology and bring the next generation of cancer therapies to patients sooner.

Let's Connect
  1. Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Annals of Oncology. 2019;30(7):1121-1126.
  2. Ramalingam SS, Gray JE, Ohe Y, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Annals of Oncology 2019;30(5):v851-v934.
  3. Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. J Clin Oncol. 2019;37(28):2518-2527.
  4. Camidge DR, Dziadziuszko R, Peters S, et al. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALKPositive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019;14(7):1233-1243.
  5. https://www.hcp.novartis.com/products/tafinlar-mekinist/metastatic-nsclc/efficacy/ Accessed online Jan. 10, 2020.
  6. Gadgeel SM, Garassino MC, Esteban E, et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. J Clin Oncol. 2019;37(suppl; abstr 9013).
  7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;14;355(24):2542-2550.
  8. Guardant360 CDx Technical Information. 2021.